Thrombosis research · 2025
"Who am I to say that I'm not going to take it": patient perspectives on decisions about antithrombotic therapy in the context of advanced cancer.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Baddeley Elin, Font Carme, Mahé Isabelle, Edwards Michelle, Sivell Stephanie, Lifford Kate J, Arfuch Victoria Mailen, Coma-Auli Nuri, Søgaard Mette, Enggaard Helle, Helfer Hélène, Mohammed Nassima Si, Seddon Kathy, Pearson Mark, Mooijaart Simone P, Szmit Sebastian, Klok F A, Noble Simon, Højen Anette Arbjerg, SERENITY consortium
Аннотация
INTRODUCTION: The decision to reconsider antithrombotic therapy (ATT) in cancer patients nearing the end of life is complex given the increasing risk of haemorrhage and thrombosis. A decision support tool (DST) is being developed to facilitate this process. Understanding patients' experiences, values, and perspectives are an essential component, yet remain largely unexplored.
AIM: To explore these patients' experiences, values and perspectives regarding ATT use.
METHODS: Qualitative study using semi-structured interviews with patients with advanced cancer receiving ATT, across Denmark, France, Spain, and the United Kingdom. Data were analysed using Framework Analysis.
RESULTS: Sixty patients and 13 relatives participated. Three major themes were generated: CONCLUSION: Patients found decision-making around ATT near the end of life multifaceted, occurring amid a myriad of competing priorities. While patients reported a reticence to discontinuing, ultimately many deferred such decisions to a clinician, whose role was highly valued. These findings support a need for a DST, to support informed and shared choices in ATT decisions.
AIM: To explore these patients' experiences, values and perspectives regarding ATT use.
METHODS: Qualitative study using semi-structured interviews with patients with advanced cancer receiving ATT, across Denmark, France, Spain, and the United Kingdom. Data were analysed using Framework Analysis.
RESULTS: Sixty patients and 13 relatives participated. Three major themes were generated: CONCLUSION: Patients found decision-making around ATT near the end of life multifaceted, occurring amid a myriad of competing priorities. While patients reported a reticence to discontinuing, ultimately many deferred such decisions to a clinician, whose role was highly valued. These findings support a need for a DST, to support informed and shared choices in ATT decisions.